EUCTR2019-004118-33-DE进行中（未招募）1 期
A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injuredpatients at risk of acute traumatic coagulopathy. - PATCH
niversität Witten/Herdecke0 个研究点目标入组 1,316 人开始时间: 2020年6月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,316
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult patients (age =18 years);
- •2. Injured through any mechanism;
- •3. COAST score =3;
- •4. First dose of study drug can be administered within three hours of injury; and
- •5. Patients to be transported to a participating trauma centre.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •1. Suspected pregnancy
- •2. Nursing home residents
研究者
相似试验
Unknown
2 期
A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexateCTRI/2009/091/000569Arana Therapeutics Limited Level 2, 37 Epping Road Macquarie Park NSW 2113 AUSTRALIA200
进行中（未招募）
不适用
A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexateMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2008-006930-92-CZArana Therapeutics Ltd200
进行中（未招募）
不适用
A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2Rheumatoid arthritisEUCTR2007-003508-36-DEitec Pharma AG350
进行中（未招募）
不适用
A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2007-003508-36-HUitec Pharma AG350
进行中（未招募）
1 期
A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis - CAPRA-2Rheumatoid arthritisEUCTR2007-003508-36-GBitec Pharma AG